antitrust law in healthcare

40
Antitrust Law in Healthcare Kim C. Stanger (BSU 3/15)

Upload: holland-hart-llp

Post on 10-Apr-2017

513 views

Category:

Healthcare


0 download

TRANSCRIPT

Page 1: Antitrust Law in Healthcare

Antitrust Law in Healthcare

Kim C. Stanger

(BSU 3/15)

Page 2: Antitrust Law in Healthcare

This presentation is similar to any other legal education materials designed to provide general information on pertinent legal topics. The statements made as part of the presentation are provided for educational purposes only. They do not constitute legal advice nor do they necessarily reflect the views of Holland & Hart LLP or any of its attorneys other than the speaker. This presentation is not intended to create an attorney-client relationship between you and Holland & Hart LLP. If you have specific questions as to the application of law to your activities, you should seek the advice of your legal counsel.

Page 3: Antitrust Law in Healthcare

History• In late 1800’s, large

corporate conglomerates (“trusts”) held monopolies, e.g.,– Standard Oil– Steel– Railroads– Copper – Sugar– Others

• Their power allowed them to:– Control prices.– Restrict competition

Page 4: Antitrust Law in Healthcare

History• Federal antitrust

laws– Sherman Act– Clayton Act– Federal Trade

Comm’n Act– Robinson-Patman Act– Hart–Scott–Rodino

Antitrust Improvements Act

• State antitrust laws– IC 48-101 et seq.

Page 5: Antitrust Law in Healthcare

Enforcement

• Federal laws– Dept of Justice (“DOJ”)• Antitrust Division

– Federal Trade Commission (“FTC”)• State laws– Attorney generals

• Private lawsuits

Page 6: Antitrust Law in Healthcare

Enforcement• Criminal penalties

– Significant fines– Prison

• Civil penalties– Action by state or federal government

• Treble (3x) damages• Injunctive relief, e.g, divestiture, break up

corporation, requirements for contracting, etc.• Attorneys fees

– Private lawsuit• Treble damages• Injunctive relief• Attorneys fees

Page 7: Antitrust Law in Healthcare

Sherman Act § 1

Competitor

Competitor

Page 8: Antitrust Law in Healthcare

Sherman Act § 1• “Every contract, combination in the form of trust

or otherwise, or conspiracy, in restraint of trade … is declared to be illegal. Every person who shall make any contract or engage in any combination or conspiracy hereby declared to be illegal shall be deemed guilty of a felony, and, on conviction thereof, shall be punished by fine not exceeding $100,000,000 if a corporation, or, if any other person, $1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion of the court.”

(15 USC § 1)

Page 9: Antitrust Law in Healthcare

Sherman Act § 1• Violation requires all of the following:

1. Contract, combination or conspiracy involving at least two independent parties.• Corporate officers and employees = same

entity.• Members of same group practice = same entity.

2. An effect on interstate commerce.• Easy to satisfy.

3. Unreasonable restraint of trade.• Per se• Rule of reason• Quick look analysis

Standards for analyzing potential violations.

Page 10: Antitrust Law in Healthcare

Sherman Act § 1

Pro-Competition Anti-Competition

Pro-competitive effects of proposed action

Anti-competitive effects of proposed action

Rule of Reason = court balances pro-competitive effects against anti-competitive effects.

Parties present evidence of pro- and anti-competitive effects.

Page 11: Antitrust Law in Healthcare

Sherman Act § 1

Pro-competition Anti-competition

Per se = certain conduct is presumed to result in unreasonable restraint of trade and is per se unlawful.

Because conduct is deemed to unreasonably restrain trade, the plaintiff is not required to present evidence of effects.

Page 12: Antitrust Law in Healthcare

Sherman Act § 1• Price fixing = competitors conspire or collude on prices.– May determine your own prices.– May not collude with others to agree on prices.• Express agreement.• Implied agreement, e.g.,–Sharing price info.–Using same person to negotiate prices.

– Applies to agreements re minimum or maximum prices.• Price fixing is usually per se illegal.• DOJ/FTC Guidelines create safety zone under which some

sharing of price info may be permitted or analyzed under rule of reason if:– Clinical integration– Financial integration

Test: do efficiencies > anti-competitive effects?

Page 13: Antitrust Law in Healthcare

Sherman Act § 1• Boycotts = competitors agree not to deal with

another entity.– May decide on your own not to do business with an

entity.– May not agree with others that none of you will do

business with the entity as a way to pressure other party.• Does not apply to labor strikes.

• Boycotts are usually per se illegal.• DOJ/FTC Guidelines create safety zone under which

some sharing of price info may be permitted or analyzed under rule of reason if sufficient integration.

Page 14: Antitrust Law in Healthcare
Page 15: Antitrust Law in Healthcare

Sherman Act § 1

• United States v. Idaho Orthpaedic Society (2010)– Complaint alleged that orthopedists:• Agreed not to treat most patients covered

by workers comp insurance to force Idaho Industrial Comm’n to increase reimbursement to orthopedists.• Agreed to threatened to terminate

contracts with Blue Cross unless Blue Cross offered more favorable terms to orthopedists.

Page 16: Antitrust Law in Healthcare

Sherman Act § 1

• United States v. Idaho Orthopaedic Society (2010)– Settlement agreement includes, e.g.,

• Prohibited from entering agreement concerning fees or other terms with payers or refusing to deal with payers.

• Prohibited from communicating with competitors re acceptability of payer terms or response to same.

• Certification of compliance for 10 years.• Subject to periodic audits.

– Settlement agreement does not prohibit:• Noerr-Pennington actions.• Participating in clinically or financially integrated

networks.

Page 17: Antitrust Law in Healthcare

Sherman Act § 1

• Market allocation = competitors agree to divide up market.–May decide on your own what items or

services to offer, or where to do business.–May not agree with competitors to divide up

markets or services.• Geographic territories• Products• Services

• Market allocations are usually per se illegal.

Page 18: Antitrust Law in Healthcare

Sherman Act § 2

Page 19: Antitrust Law in Healthcare

Sherman Act § 2• “Every person who shall monopolize, or attempt

to monopolize, or combine or conspire with any other person or persons, to monopolize any part of the trade or commerce among the several States, or with foreign nations, shall be deemed guilty of a felony, and, on conviction thereof, shall be punished by fine not exceeding $100,000,000 if a corporation, or, if any other person, $1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion of the court.”

(15 USC § 2)

Page 20: Antitrust Law in Healthcare

Sherman Act § 2

• Having monopoly power alone is not a violation.

• E.g., having better product or greater skill• E.g., CON, govt franchise, or patent.

• Violation requires both:1. Monopoly power in a relevant market; and2. Willful acquisition or maintenance of that

monopoly power through use of coercive or inappropriate acts.• E.g., predatory pricing.

Page 21: Antitrust Law in Healthcare

Clayton Act § 7

Page 22: Antitrust Law in Healthcare

Clayton Act § 7

• “No person … shall acquire the whole or any part of the assets of another person engaged also in commerce or in any activity affecting commerce, where … the effect of such acquisition may be substantially to lessen competition, or to tend to create a monopoly.”

(15 USC § 18)

Page 23: Antitrust Law in Healthcare

Clayton Act § 7 • To establish violation:

1. Determine relevant market.• Market = is the area of effective competition where

buyers can turn for alternate sources of supply.• Test = whether monopolist in the proposed market

could impose increase in prices.2. Determine whether the merger will have anti-

competitive effects in the relevant market.• Adverse effects on competition if there is merger.• Existing competition in the market.• Likelihood of other competitors entering market.• Efficiencies resulting from merger that could not be

achieved through other means (“merger-specific”).• Whether one party would fail if there is no merger.

Page 24: Antitrust Law in Healthcare

Clayton Act § 7

Horizontal Mergers• Mergers of

competitors at same level of production or distribution (e.g., merger of competing sellers of same product)

• DOJ/FTC Horizontal Merger Guidelines

Vertical Mergers• Mergers of

competitors at different levels of production or distribution (e.g., merger of manufacturer and retailer)

Page 25: Antitrust Law in Healthcare

Clayton ActFTC v. St. Luke’s (Id. 2015)• St. Luke’s acquired Saltzer

Medical Group, one of the largest independent practice groups in Idaho.

• Competitors St. Alphonsus and Treasure Valley Hospital sued, claiming the acquisition gave St. Luke’s 80% of the primary care physicians (“PCPs”) in the Nampa, Idaho market.

• FTC and Idaho Attorney General joined in lawsuit.

• In 2014, US District judge held that, while transaction was well-intentioned, it would result in anti-competitive effects and ordered Saltzer sale unwound.

• In 2015, Ninth Circuit affirmed the decision.

Page 26: Antitrust Law in Healthcare

Clayton Act § 7

Boise and Nampa are only 20 miles apart. Prior to merger:

Saltzer had 16 PCPs. St. Luke’s had 8 PCPs. St. Als had 9 PCPs. There were several solo PCPs.

27 PCPs

Page 27: Antitrust Law in Healthcare

Clayton Act § 7

St. Luke’s court found that Nampa was the relevant market.• Nampa consumers strongly prefer local PCP.• Insurers must include Nampa PCPs in

product to remain competitive.• Merger would allow St. Luke’s to demand

increased prices to insurers who wished to do business in Nampa.

• Consumers would pay increased prices rather than drive to Boise.

Page 28: Antitrust Law in Healthcare

Clayton Act § 7 St. Luke’s court found merger anti-competitive effects.• St. Luke’s + Saltzer = 80% of PCPs in Nampa market.• St. Luke’s would likely use power to negotiate higher

rates for PCPs.– Internal correspondence suggested that merger

would allow St. Luke’s to pressure insurers to pay increases.

– Following St. Luke’s acquisition in Twin Falls, St. Luke’s allegedly used its leverage to obtain higher prices from insurers.

• St. Luke’s might use power to negotiate higher rates for ancillaries.– But 9th Circuit held this finding was not supported

by the record.• Difficult for competitors to enter market.• St. Luke’s could achieve benefits by other means

apart from merger (i.e., they were not “merger specific”).

Page 29: Antitrust Law in Healthcare

Clayton Act § 7 • “Antitrust enforcement of vertical integration

[i.e., acquisitions] among health care providers is best judged on a case-by-case basis. Transactions that promise to improve the delivery of care and that pose no threat of increased prices or other competitive harm should be allowed. But we stand ready to take appropriate enforcement action against transactions that harm competition.” (Assistant Attorney General William J. Baer, Chief of the Justice Department's Antitrust Division)

Page 30: Antitrust Law in Healthcare

Antitrust Defenses

Page 31: Antitrust Law in Healthcare

State Action Immunity• Congress did not intend the antitrust laws to

apply to state action.• States can regulate industries even though it

may affect competition (e.g., certificate of need (“CON”) laws).

• Private entities may be able to claim state action immunity if show:1. state adopted clearly articulated policy to

replace competition with regulation, and2. private conduct must be actively

supervised by the state government.

Page 32: Antitrust Law in Healthcare

State Action Immunity• North Carolina Bd of Dental Examiners v. FTC (SCt

2014)Facts:– Board threatened nondentists performing teeth

whitening with action for practicing dentistry without a license.

–Most of the Board members were practicing dentists who received significant fees from teeth whitening.

– The dental practices act did not define the practice of dentistry to include teeth whitening.

Page 33: Antitrust Law in Healthcare

State Action Immunity• North Carolina Bd of Dental Examiners v. FTC (SCt

2014)Analysis:– Nonsovereign actor receives state action immunity only if:• Challenged restraint is clearly articulated in state policy;

and• The policy is actively supervised by the state.

– In this case, Supreme Court held that:• Board comprised of active market participants must be

actively supervised by the state.• There as no active supervision by state:

–State delegated authority to Board.– “Teeth whitening” not addressed in statue.–No evidence of state involvement.

Page 34: Antitrust Law in Healthcare

Antitrust Defense

• Local Govt Antitrust Act– Local govt units are immune from

antitrust damages.–May still be subject to injunctive relief.

Page 35: Antitrust Law in Healthcare

Antitrust Defense• Health Care Quality Improvement Act (“HCQIA”)– Enacted to encourage health care providers to engage in

peer review activity and report adverse action against physicians.

– Participants in peer review activity are immune from private lawsuits for damages if:• Physician is given minimal due process, e.g., notice

and hearing; and• Hospital or other facility reports adverse peer review

activity to the National Practitioners Data Bank (“NPDB”).

– Participants may still be liable for:• Injunctive relief.• Civil rights claims.

Page 36: Antitrust Law in Healthcare

Antitrust Defense

• Noerr-Pennington Doctrine– Requesting action by government is

protected by the First Amendment and does not violate antitrust law even if the intent or result is to acquire or maintain a monopoly, e.g.,• Objecting to CON of competitor.• Physicians petition legislature or

agency to restrict scope of license of other practitioners.

– Does not apply if action was a sham.

Page 37: Antitrust Law in Healthcare

DOJ/FTC Statements of Antitrust Enforcement Policy in Health Care

• Outlines DOJ/FTC enforcement policy for specific situations, e.g.• Mergers• Joint ventures• Networks• Sharing price

info• Includes “safety

zones” in which DOJ/FTC will not challenge action absent extraordinary circumstances.

Page 38: Antitrust Law in Healthcare

DOJ/FTC Statements of Antitrust Enforcement Policy Regarding Accountable Care Organizations

Page 39: Antitrust Law in Healthcare
Page 40: Antitrust Law in Healthcare

Assignment

• Activity 9.1 at pp.214-217.